Academic Journal
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL
| العنوان: | Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL |
|---|---|
| المؤلفون: | Arevalo, Aileen, Patel, Neal, Muraki, Peter, Ohtake, Shinji, Bratslavsky, Gennady, Clark, Chandra, Mann, Joshua, Iliopoulos, Othon, Jonasch, Eric, Srinivasan, Ramaprasad, Shuch, Brian |
| المصدر: | Journal of Kidney Cancer and VHL; Vol. 9 No. 3 (2022): Journal of Kidney Cancer and VHL; 41-46 ; 2203-5826 |
| بيانات النشر: | Codon Publications |
| سنة النشر: | 2022 |
| المجموعة: | Journal of Kidney Cancer and VHL (JKCVHL) |
| مصطلحات موضوعية: | VHL, kidney cancer, systemic therapy |
| الوصف: | Belzutifan was recently approved for the management of Von Hippel–Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL experts in the United States. A survey developed by members of the VHL Alliance (VHLA) Clinical Advisory Council was distributed to kidney cancer providers at VHLA and National Comprehensive Cancer Network (NCCN) centers. Surveys were administered on a secure web-based platform. A total of 60 respondents from 29 institutions participated. Urologists (50%) and medical oncologists (43%) represented the majority of participants. The majority (98%) of respondents anticipated that belzutifan’s approval would signifi-cantly change the current treatment landscape. Most reported that therapy should be continuous (76%). There was a difference in willingness to prescribe belzutifan by specialty (38% of urologists vs 91% of medical oncologists (P = 0.02). In individuals with renal tumors <3 cm, 36% would still recommend surveillance, while 36% would initiate belzutifan to prevent growth. In those with multifocal renal lesions and growth of a solitary tumor on belzutifan, 50% would proceed with only treatment of that site. In conclusion, VHL kidney cancer specialists anticipate a paradigm shift with the approval of belzutifan. Provider roles may change with movement away from surgical management. Opinions on treatment indications, such as when to initiate therapy and how to best salvage, vary widely and collaborative efforts among experts may assist in the development of clinical guidelines. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf; text/html; text/xml |
| اللغة: | English |
| Relation: | https://jkcvhl.com/index.php/jkcvhl/article/view/245/430; https://jkcvhl.com/index.php/jkcvhl/article/view/245/432; https://jkcvhl.com/index.php/jkcvhl/article/view/245/431; https://jkcvhl.com/index.php/jkcvhl/article/view/245 |
| DOI: | 10.15586/jkcvhl.v9i3.245 |
| الاتاحة: | https://jkcvhl.com/index.php/jkcvhl/article/view/245 https://doi.org/10.15586/jkcvhl.v9i3.245 |
| Rights: | Copyright (c) 2022 Neal Patel, Aileen Arevalo , Peter Muraki, Shinji Ohtake, Gennady Bratslavsky, Chandra Clark, Joshua Mann, Othon Iliopoulos, Eric Jonasch , Ramaprasad Srinivasan, Brian Shuch ; https://creativecommons.org/licenses/by-nc-nd/4.0 |
| رقم الانضمام: | edsbas.DD7D7AE4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.15586/jkcvhl.v9i3.245 |
|---|